双鹭药业：2025年预计净亏2亿 - 2.9亿元，同比降幅扩大

Group 1 - The company expects a net profit attributable to shareholders to be between -290 million to -200 million yuan for 2025, a decline of 291.54% to 170.03% compared to the same period last year, which reported -74.0657 million yuan [1] - The non-recurring net profit is projected to be between -70 million to -40 million yuan, a decrease of 185.02% to 148.58% from the previous year's 82.3370 million yuan [1] - The decline in performance is primarily due to industry policies and competition leading to a decrease in product prices, with sales gross margin dropping by approximately 10%, and non-recurring gains and losses reducing net profit by about 200 million yuan [1] Group 2 - The chairman, Xu Mingbo, has committed to cover the irretrievable gap from investment and financial management, initially contributing 50 million yuan [1]